Crescent Biopharma, Inc.

NASDAQ:CBIOHealthcare · Biotechnology

Mkt Cap$500.74M

Float20.86M

Shares O/S37.15M

Inst Own79.5%

SI21.2%

Dilution

-4.19%$13.48

AH$13.67+1.41%vs close

Mkt Cap$500.74M

Float20.86M

O/S37.15M

Vol

$ Vol

RVOL

Inst Own79.5%

SI21.2%

Earnings

Dilution

NASDAQ:CBIO$13.48-4.19%

MCap$500.74M

Float20.86M

O/S37.15M

SI21.2%

Inst Own79.5%

Dilution

Phase Distribution

19 lead-sponsored trials·1 active·14 completed

Phase 112

Phase 1/24

Phase 21

Phase 32

(5 more as collaborator)

Status Overview

Recruiting1

Completed14

Stopped4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials

Sponsor role

Status

Phase

Phase 3
Terminated
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
Rivipansel
Sickle Cell Anemia, Sickle Cell Disease +3
Enrollment
154
Start
Dec 2015
Primary Completion
Nov 2019
Completion
Nov 2019
NCT02433158
Phase 3
Terminated
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Uproleselan, Placebo
Acute Myeloid Leukemia
Enrollment
388
Start
Oct 2018
Primary Completion
Mar 2024
Completion
Mar 2024
NCT03616470
Phase 2
Completed
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
GMI-1070, Placebo
Sickle Cell Disease, Vaso-occlusive Crisis +1
Enrollment
81
Start
May 2010
Primary Completion
Dec 2012
Completion
Dec 2013
NCT01119833
Phase 1/2
Completed
Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
GMI-1070
Sickle Cell Disease
Enrollment
15
Start
May 2009
Primary Completion
Jul 2010
Completion
Sep 2010
NCT00911495
Phase 1/2
Completed
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
GMI-1271, Mitoxantrone
Leukemia, Myeloid, Acute
Enrollment
91
Start
Mar 2015
Primary Completion
Dec 2017
Completion
May 2018
NCT02306291
Phase 1/2
Terminated
Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)
GMI-1271, Enoxaparin Sodium (Lovenox®)
Deep Venous Thrombosis
Enrollment
2
Start
Jul 2016
Primary Completion
Nov 2016
Completion
Nov 2016
NCT02744833
Phase 1/2
Recruiting
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
CR-001, Paclitaxel
Locally Advanced / Metastatic Solid Tumors
Enrollment
540
Start
Feb 2026
Primary Completion
Feb 2029est.
Completion
Feb 2029est.
NCT07335497
Phase 1
Completed
A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects
Rivipansel
Healthy
Enrollment
48
Start
Aug 2013
Primary Completion
Aug 2014
Completion
Aug 2014
NCT01941511
Phase 1
Completed
Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers
GMI-1271, Placebo
Healthy Adult Subjects
Enrollment
28
Start
Jun 2014
Primary Completion
Aug 2014
Completion
Apr 2015
NCT02168595
Phase 1
Completed
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects
Rivipansel, Placebo
Healthy
Enrollment
27
Start
Oct 2015
Primary Completion
Apr 2016
Completion
Apr 2016
NCT02217917
Phase 1
Completed
Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects
GMI-1271, Placebo
Healthy Volunteers
Enrollment
32
Start
Oct 2014
Primary Completion
Mar 2016
Completion
Mar 2016
NCT02271113
Phase 1
Completed
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
GMI-1271, Filgrastim
Healthy Volunteers
Enrollment
54
Start
Nov 2015
Primary Completion
Aug 2016
Completion
Aug 2016
NCT02703051
Phase 1
Completed
A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma
GMI-1271
Multiple Myeloma
Enrollment
10
Start
Jun 2016
Primary Completion
Apr 2019
Completion
Apr 2019
NCT02811822
Phase 1
Completed
A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects
Rivipansel
Renal Impairment, Healthy
Enrollment
28
Start
Jun 2016
Primary Completion
Feb 2018
Completion
Feb 2018
NCT02813798
Phase 1
Completed
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
Rivipansel
Moderate Hepatic Impairment, Normal Hepatic Function
Enrollment
16
Start
Sep 2016
Primary Completion
Feb 2017
Completion
Mar 2017
NCT02871570
Phase 1
Completed
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers
GMI-1359, Placebo
Healthy
Enrollment
58
Start
Aug 2016
Primary Completion
Oct 2017
Completion
Nov 2018
NCT02931214
Phase 1
Completed
A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.
Rivipansel
Healthy
Enrollment
16
Start
Jan 2017
Primary Completion
Feb 2017
Completion
Mar 2017
NCT02998099
Phase 1
Completed
A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)
Uproleselan
Healthy Subjects
Enrollment
5
Start
Aug 2018
Primary Completion
Sep 2018
Completion
Sep 2018
NCT03606447
Phase 1
Terminated
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
GMI-1359
HR+ Metastatic Breast Cancer, Breast Cancer +1
Enrollment
4
Start
Nov 2019
Primary Completion
Aug 2021
Completion
Aug 2021
NCT04197999

		Drug / Therapy	Title	Conditions	Enrollment				Link
Phase 3	Terminated	Rivipansel	Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease	Sickle Cell Anemia, Sickle Cell Disease	154	Dec 2015	Nov 2019	Nov 2019	NCT02433158
Phase 3	Terminated	Uproleselan, Placebo	Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia	Acute Myeloid Leukemia	388	Oct 2018	Mar 2024	Mar 2024	NCT03616470
Phase 2	Completed	GMI-1070, Placebo	Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis	Sickle Cell Disease, Vaso-occlusive Crisis	81	May 2010	Dec 2012	Dec 2013	NCT01119833
Phase 1/2	Completed	GMI-1070	Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease	Sickle Cell Disease	15	May 2009	Jul 2010	Sep 2010	NCT00911495
Phase 1/2	Completed	GMI-1271, Mitoxantrone	Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML	Leukemia, Myeloid, Acute	91	Mar 2015	Dec 2017	May 2018	NCT02306291
Phase 1/2	Terminated	GMI-1271, Enoxaparin Sodium (Lovenox®)	Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)	Deep Venous Thrombosis	2	Jul 2016	Nov 2016	Nov 2016	NCT02744833
Phase 1/2	Recruiting	CR-001, Paclitaxel	CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors	Locally Advanced / Metastatic Solid Tumors	540	Feb 2026	Feb 2029est.	Feb 2029est.	NCT07335497
Phase 1	Completed	Rivipansel	A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects	Healthy	48	Aug 2013	Aug 2014	Aug 2014	NCT01941511
Phase 1	Completed	GMI-1271, Placebo	Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers	Healthy Adult Subjects	28	Jun 2014	Aug 2014	Apr 2015	NCT02168595
Phase 1	Completed	Rivipansel, Placebo	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects	Healthy	27	Oct 2015	Apr 2016	Apr 2016	NCT02217917
Phase 1	Completed	GMI-1271, Placebo	Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects	Healthy Volunteers	32	Oct 2014	Mar 2016	Mar 2016	NCT02271113
Phase 1	Completed	GMI-1271, Filgrastim	A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects	Healthy Volunteers	54	Nov 2015	Aug 2016	Aug 2016	NCT02703051
Phase 1	Completed	GMI-1271	A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma	Multiple Myeloma	10	Jun 2016	Apr 2019	Apr 2019	NCT02811822
Phase 1	Completed	Rivipansel	A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects	Renal Impairment, Healthy	28	Jun 2016	Feb 2018	Feb 2018	NCT02813798
Phase 1	Completed	Rivipansel	A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function	Moderate Hepatic Impairment, Normal Hepatic Function	16	Sep 2016	Feb 2017	Mar 2017	NCT02871570
Phase 1	Completed	GMI-1359, Placebo	Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers	Healthy	58	Aug 2016	Oct 2017	Nov 2018	NCT02931214
Phase 1	Completed	Rivipansel	A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.	Healthy	16	Jan 2017	Feb 2017	Mar 2017	NCT02998099
Phase 1	Completed	Uproleselan	A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)	Healthy Subjects	5	Aug 2018	Sep 2018	Sep 2018	NCT03606447
Phase 1	Terminated	GMI-1359	A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer	HR+ Metastatic Breast Cancer, Breast Cancer	4	Nov 2019	Aug 2021	Aug 2021	NCT04197999

Search ClinicalTrials.gov for “Crescent Biopharma”